Form 4: Drugs Made In America Acquisition LLC Reports Ownership Changes

Drugs Made In America Acquisition LLC, a 10% owner of Drugs Made In America Acquisition Corp., reports transactions involving ordinary shares and rights to receive ordinary shares.

Summary

• Drugs Made In America Acquisition LLC filed a Form 4 detailing changes in beneficial ownership of Drugs Made In America Acquisition Corp.
• On January 29, 2025, the reporting person purchased 400,000 ordinary shares.
• The reporting person also transferred 400,000 ordinary shares to officers and directors for no consideration.
• Additionally, 5,698,363 ordinary shares were transferred for consideration ranging from no consideration to $1.50 per share.
• The reporting person directly owns 4,158,780 ordinary shares following these transactions.
• The reporting person also owns rights to receive 400,000 ordinary shares upon the consummation of an initial business combination.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing ownership changes, with no inherent positive or negative sentiment. It reflects normal transactions within the company's structure.

Future Outlook

The rights to receive ordinary shares will convert automatically upon the completion of the Issuer's initial business combination.

Industry Context

This filing is a routine disclosure related to changes in ownership for special purpose acquisition companies (SPACs) like Drugs Made In America Acquisition Corp. These filings are common as sponsors and insiders adjust their holdings.

Comparison to Industry Standards

• SPAC sponsors typically receive shares at nominal prices before the IPO, similar to the transfers described in this filing.
• The transfer of shares to officers and directors is a common practice to align their interests with the success of the SPAC.
• The $10 per unit purchase price for private units is standard for SPACs.

Related Party Transactions

• The transfer of 400,000 ordinary shares to the Issuer's officers and directors can be considered a related party transaction.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership distribution.
• The transfer of shares to officers and directors could incentivize them to work towards a successful business combination.

Key Dates

Keywords

beneficial ownership, Form 4, ordinary shares, Drugs Made In America Acquisition Corp., DMAA, Drugs Made In America Acquisition LLC, share transfer, initial business combination, rights